Oramed Pharmaceuticals (ORMP)
Develops oral formulations for insulin and other therapeutic proteins.
Something off on this page? Send us feedback.
Develops oral-delivery formulations for therapeutic proteins, with oral insulin as its core development program. Its current context also includes strategic healthcare and life-sciences investments, financing, and real-estate transactions.
Develops oral-delivery formulations for therapeutic proteins, designed to protect insulin and other proteins through the gastrointestinal environment without chemically or biologically modifying the protein. No commercialized therapeutic product is described in the current filing.
Oral insulin is the core development program and ORMD-0801 was its former flagship candidate. A U.S. Phase 3 study reported in 2023 did not meet its primary or secondary endpoint; the company now intends a narrower planned U.S. trial through OraTech to test formulation robustness and refine patient selection.
Alongside pharmaceutical development, capital is allocated to strategic healthcare and life-sciences investments as well as financing and real-estate transactions. Clinical execution, regulatory approvals, and outcomes from financial investments shape the business.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $50.6M · Total debt $733.0K · Total assets $369.6M · Shareholders' equity $317.5M
- Revenue
- $0
- Operating income
- −$2.8M
- Net income
- $78.2M
| Institutions | 40.52% | 16.86M shares | |
|---|---|---|---|
| 86 holders · as of Jun 30, 2026 | |||
| Insiders | 8.47% | 3.52M shares | |
| 8 holders · as of Jul 2, 2026 | |||
| Other | 51.01% | 21.22M shares | |
| remainder | |||
41.60M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Mercer Global Advisors Inc /AdvInstitution | 9.16% | 3.81M | as of Jun 30, 2026 |
Aquamarine Financial (Cayman) LtdInstitution | 6.04% | 2.51M | as of Jun 30, 2026 |
BML Investment Partners, L.P.Institution | 4.92% | 2.05M | filed Sep 16, 2024 |
Gem Investment Advisors, LLCInstitution | 4.81% | 2.00M | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 3.87% | 1.61M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jul 1, 2026 | Avraham Gabay | officer: Chief Financial Officer | −73,360 | $4.51 |
| Jul 1, 2026 | Joshua Hexter | officer: COO & CBO | −137,000 | $4.46 |
- Novo Nordisk (ADR)
Diabetes leader across insulin and oral GLP-1 therapy
- Eli Lilly
Large diabetes franchise spanning insulin and incretin medicines
- Sanofi (ADR)
Established basal-insulin supplier with Lantus and Toujeo
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Oramed Pharmaceuticals | $4.69 | −1.26% | $194.4M | 1.2 | — | — | — |
| Novo Nordisk (ADR) | $38.24 | −2.96% | $174.96B | 9.9 | 15.8 | 3.5 | +1.3% |
| Eli Lilly | $1,152.13 | −1.54% | $1.10T | 39.3 | 28.2 | 13.8 | +47.7% |
| Sanofi (ADR) | $41.50 | −2.39% | $102.08B | 76.0 | — | 1.8 | +11.2% |
| Median | 39.3 | 22.0 | 3.5 | +11.2% |